



Stabilis



Metronidazole



Stabilita farmaceutických přípravků

		750 mg ® = ?	TrichoSol® > 10 ml	25°C		180		4921




Odkazy

	typ	uveřejnění
4921	noviny	Schettino C, Marianni B, Polonini H. Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride, Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions. Int J Pharm Compound 2025 ;29,1:64-76

Stabilis



Metronidazole



Obchodní název

Amrizole	Egypt, Saúdská Arábie, Spojené arabské emiráty
Anaerobex	Rakousko
Bactrizol	Venezuela
Colpocin	česko
Deflamon	Itálie
Dumozol	Egypt, Portugalsko
Efloran	Chorvatsko
Elyzol	Saúdská Arábie
Emedal	česko
Femagin	Malajsie
Flagyl	Česko, Brazílie, Chile, Egypt, Ekvádor, Francie, Irsko, Island, Kolumbie, Lucembursko, Maroko, Mexiko, Nizozemsko, Norsko, Peru, Turecko, USA, česko
Flaxtec	Mexiko
Flazol	Egypt
Flegyl	Venezuela
Gnostol	česko
Klion	Maŕsko
Medazol	Mexiko
Metrolag	Spojené arabské emiráty, Švýcarsko
Metronidazole	Austrálie, Belgie, Egypt, Finsko, Francie, Írán, Irsko, Malajsie, Maroko, Norsko, nový Zéland, Portugalsko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Tunisko, Velká Británie, česko
Nidazol	Írán, Saúdská Arábie, Spojené arabské emiráty, Turecko



Stabilita směsí

		2 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20		630
		2.6 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2228
		2,5 mg/ml	23°C		Levofloxacin : 2,5 mg/ml	3		1988

		5 mg/ml	25°C		Cefoxitin sodium : 30 mg/ml	2		631
		5 mg/ml	25°C		Cefoxitin sodium : 30 mg/ml	2		631
		5 mg/ml	25°C		Moxalactam : 20 mg/ml	2		631
		5 mg/ml	25°C		Penicillin G potassium : 0,2 MUI/ml	3		631
		5 mg/ml	25°C		Cefazolin sodium : 10 mg/ml	7		631
		5 mg/ml	25°C		Hydrocortisone sodium succinate : 10 mg/ml	7		631
		5 mg/ml	25°C		Ampicillin sodium : 20 mg/ml	22		631
		5 mg/ml	5°C		Ampicillin sodium : 20 mg/ml	12		631
		5 mg/ml	5°C		Cefazolin sodium : 10 mg/ml	12		631
		5 mg/ml	5°C		Cefoxitin sodium : 30 mg/ml	12		631
		5 mg/ml	5°C		Cefalotin sodium : 20 mg/ml	12		631
		5 mg/ml	5°C		Hydrocortisone sodium succinate : 10 mg/ml	12		631
		5 mg/ml	5°C		Penicillin G potassium : 0,2 MUI/ml	12		631
		5 mg/ml	5°C		Moxalactam : 20 mg/ml	12		631
		5 mg/ml	8°C		Cefazolin sodium : 10 mg/ml	3		671
		7,5 mg/ml	24-26°C		Ceftriaxone disodium : 10 mg/ml	24		11
		4 mg/ml	25°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		5 mg/ml	28°C		Cefotaxime sodium : 10 mg/ml	12		281
		7,5 mg/ml	4-6°C		Ceftriaxone disodium : 10 mg/ml	72		11
		4 mg/ml	4°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		5 mg/ml	5°C		Cefotaxime sodium : 10 mg/ml	96		281
		7,5 mg/ml	24-26°C		Ceftriaxone disodium : 10 mg/ml	24		11
		4 mg/ml	25°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		7,5 mg/ml	4-6°C		Ceftriaxone disodium : 10 mg/ml	72		11
		4 mg/ml	4°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 2,5 & 20 mg/ml	2		1605
		5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 5 mg/ml	4		1605
		5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 10 mg/ml	5		1605
		5 mg/ml	25°C		Ceftriaxone disodium : 10 mg/ml	3		649
		5 mg/ml	25°C		Ceftizoxime sodium : 10 mg/ml	3		267
		5 mg/ml	4°C		Cefuroxime sodium : 7,5 mg/ml	7		961
		5 mg/ml	4°C		Ceftizoxime sodium : 10 mg/ml	14		267
		5 mg/ml	4°C		Cefepime dihydrochloride : 2,5 >> 20 mg/ml	7		1605

PVC	Ø	5 mg/ml	8°C	?	Ceftizoxime sodium : 10 mg/ml	72	✓	282
PVC	Ø	5 mg/ml	8°C	?	Ceftriaxone disodium : 10 mg/ml	72	✓	282
PVC	Ø	5 mg/ml	8°C	?	Ceftazidime : 10 mg/ml	72	✓	282
?	Ø	4,1 mg/ml	20°C	☀	Cefamandole nafate : 16,6 mg/ml	4	✓	1479
?	Ø	5 mg/ml	25°C	☀	Piperacillin sodium : 40 mg/ml	4	✓	1692



Faktory ovlivňující stabilitu

				3594
---	---	---	---	------



Kompatibilita

				
	✓	Metronidazole : 5 mg/ml Aciclovir sodium : 5 mg/ml	♦	336
	✓	Metronidazole : 5 mg/ml Allopurinol sodium : 3 mg/ml	▲	307
	✓	Metronidazole : 5 mg/ml Amifostine : 10 mg/ml	♦	3
	✓	Metronidazole Amikacin sulfate		3594
	✓	Metronidazole : 5 mg/ml Amikacin sulfate : 5 mg/ml	Ø	1035
	✓	Metronidazole : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml	▲	385
	✓	Metronidazole : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml	♦	385
	✓	Metronidazole : 5 mg/ml Amiodarone hydrochloride : 6 mg/ml	♦	1611
	✓	Metronidazole : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	✗	Metronidazole : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml	♦	921
	✓	Metronidazole Ampicillin sodium		3594
	✓	Metronidazole : 5 mg/ml Ampicillin sodium : 20 mg/ml	Ø	1035
	✓	Metronidazole : 5 mg/ml Ampicillin sodium : 20 mg/ml	Ø	631
	✓	Metronidazole : 5 mg/ml Anidulafungin : 0.5 mg/ml	♦	1982
	✗	Metronidazole : 5 mg/ml Atenolol : 0,1 mg/ml	▲	4698
	✗	Metronidazole : 5 mg/ml Aztreonam : 40 mg/ml	♦	99

		Metronidazole : 5 mg/ml Aztreonam : 10 & 20 mg/ml	Ø	19
		Metronidazole Aztreonam		3547
		Metronidazole : 5 mg/ml Bivalirudin : 5 mg/ml	♦	1713
		Metronidazole : 2.5 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml	▲	3976
		Metronidazole : 5 mg/ml Caffeine : 10 mg/ml	Ø	3964
		Metronidazole : 5 mg/ml Caffeine : 10 mg/ml		4837
		Metronidazole : 5 mg/ml Caffeine citrate : 20 mg/ml		4837
		Metronidazole : 5 mg/ml Caspofungin acetate : 0.5 mg/ml	▲	2233
		Metronidazole : 5 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Metronidazole : 5 mg/ml Cefalotin sodium : 20 mg/ml	Ø	1035
		Metronidazole : 5 mg/ml Cefalotin sodium : 20 mg/ml	Ø	631
		Metronidazole Cefalotin sodium		3594
		Metronidazole Cefamandole nafate		3594
		Metronidazole : 4.17 mg/ml Cefamandole nafate : 16.67 mg/ml	Ø	1479
		Metronidazole : 5 mg/ml Cefamandole nafate : 20 mg/ml	Ø	1035
		Metronidazole : 5 mg/ml Cefazolin sodium : 10 mg/ml	Ø	1035
		Metronidazole : 5 mg/ml Cefazolin sodium : 10 mg/ml	Ø	631
		Metronidazole Cefazolin sodium		3594
		Metronidazole Cefepime dihydrochloride		3548
		Metronidazole : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
		Metronidazole : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	♦	4528
		Metronidazole : 5 mg/ml Cefotaxime sodium : 20 mg/ml	Ø	1035
		Metronidazole : 5 mg/ml Cefotaxime sodium : 10 mg/ml	Ø	281
		Metronidazole Cefotaxime sodium		3594
		Metronidazole : 5 mg/ml Cefoxitin sodium : 30 mg/ml	Ø	1035
		Metronidazole : 5 mg/ml Cefoxitin sodium : 30 mg/ml	Ø	631

		Metronidazole Cefoxitin sodium		3594
		Metronidazole : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Metronidazole : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Metronidazole : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Metronidazole : 5 mg/ml Ceftazidime : 10 mg/ml	Ø	282
		Metronidazole : 5 mg/ml Ceftizoxime sodium : 10 mg/ml	Ø	267
		Metronidazole : 5 mg/ml Ceftizoxime sodium : 10 mg/ml	Ø	282
		Metronidazole : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Metronidazole : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Metronidazole : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Metronidazole : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Metronidazole : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Metronidazole : 7.5 mg/ml Ceftriaxone disodium : 10 mg/ml		11
		Metronidazole : 15 mg/ml Ceftriaxone disodium : 20 mg/ml		11
		Metronidazole : 5 mg/ml Ceftriaxone disodium : 10 mg/ml	Ø	649
		Metronidazole : 15 mg/ml Ceftriaxone disodium : 20 mg/ml		11
		Metronidazole : 5 mg/ml Ceftriaxone disodium : 10 mg/ml	Ø	282
		Metronidazole : 7.5 mg/ml Ceftriaxone disodium : 10 mg/ml		11
		Metronidazole : 5 mg/ml Cefuroxime sodium : 7,5 mg/ml	Ø	961
		Metronidazole Cefuroxime sodium		3594
		Metronidazole : 5 mg/ml Chloramphenicol sodium succinate : 10 mg/ml	Ø	1035
		Metronidazole Chloramphenicol sodium succinate		3594
		Metronidazole : 4 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Metronidazole : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
		Metronidazole : 2.5 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Metronidazole : 4 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434

	Metronidazole : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Metronidazole Clindamycin phosphate		3594
	Metronidazole : 5 mg/ml Clindamycin phosphate : 10 mg/ml		1035
	Metronidazole : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Metronidazole Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
	Metronidazole : 5 mg/ml Defibrotide : 8 mg/ml		3728
	Metronidazole : 5 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Metronidazole : 5 & 8 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Metronidazole Dimenhydrinate		2087
	Metronidazole : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
	Metronidazole : 5 mg/ml Dopamine hydrochloride : 0.8 mg/ml		132
	Metronidazole : 5 mg/ml Doripenem : 5 mg/ml		2262
	Metronidazole : 5 mg/ml Doripenem : 5 mg/ml		2262
	Metronidazole : 5 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
	Metronidazole : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Metronidazole : 5 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Metronidazole : 5 mg/ml Eravacycline : 0,6 mg/ml		4434
	Metronidazole : 5 mg/ml Esmolol hydrochloride : 10 mg/ml		384
	Metronidazole : 5 mg/ml		316
	Metronidazole : 5 mg/ml		3948
	Metronidazole : 5 mg/ml		939
	Metronidazole : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Metronidazole : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Metronidazole : 5 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Metronidazole : 5 mg/ml Fosfomycin : 30 mg/ml		4055
	Metronidazole : 5 mg/ml Fosfomycin : 30 mg/ml		4055
	Metronidazole : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423

	Metronidazole : 5 mg/ml Gentamicin sulfate : 0,8 & 1,2 mg/ml	Ø	1243
	Metronidazole Gentamicin sulfate		3594
	Metronidazole : 5 mg/ml		301
	Metronidazole : 5 mg/ml Gentamicin sulfate : 0.8 mg/ml	Ø	1035
	Metronidazole		3594
	Metronidazole : 5 mg/ml Fentanyl citrate : 50 µg/ml		63
	Metronidazole : 5 mg/ml Filgrastim : 30 µg/ml		244
	Metronidazole : 5 mg/ml Fluconazole : 2 mg/ml	Ø	256
	Metronidazole : 5 mg/ml Fluconazole : 2 mg/ml		496
	Metronidazole : 5 mg/ml Foscarnet sodium : 24 mg/ml	Ø	73
	Metronidazole : 5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Metronidazole : 5 mg/ml Heparin sodium : 50 UI/ml	Ø	317
	Metronidazole : 5 mg/ml Hetastarch : 60 mg/ml		1721
	Metronidazole Hydrocortisone sodium succinate		3594
	Metronidazole : 5 mg/ml Hydrocortisone sodium succinate : 10 mg/ml	Ø	1035
	Metronidazole : 5 mg/ml Hydrocortisone sodium succinate : 10 mg/ml	Ø	631
	Metronidazole : 5 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
	Metronidazole : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
	Metronidazole : 5 mg/ml Labetalol hydrochloride : 1 mg/ml		386
	Metronidazole : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Metronidazole : 5 mg/ml Levofloxacin : 5 mg/ml	Ø	1988
	Metronidazole : 5 mg/ml Linezolid : 2 mg/ml	Ø	1925
	Metronidazole : 5 mg/ml Lorazepam : 0.33 mg/ml		186
	Metronidazole : 5 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
	Metronidazole : 2 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630
	Metronidazole : 5 mg/ml Melphalan : 0.1 mg/ml		169
	Metronidazole : 5 mg/ml Meropenem : 50 mg/ml		4319

	Metronidazole : 5 mg/ml Meropenem : 1 >> 50 mg/ml		266
	Metronidazole : 5 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		132
	Metronidazole : 5 mg/ml		4924
	Metronidazole : 5 mg/ml Midazolam hydrochloride : 5 mg/ml		186
	Metronidazole : 5 mg/ml Midazolam hydrochloride : 0.05 >> 0.4 mg/ml		1888
	Metronidazole : 5 mg/ml Midazolam hydrochloride : 1 mg/ml		176
	Metronidazole : 5 mg/ml Morphine sulfate : 1 mg/ml		405
	Metronidazole : 5 mg/ml Moxalactam : 20 mg/ml		631
	Metronidazole : 5 mg/ml Moxalactam : 20 mg/ml		1035
	Metronidazole : 5 mg/ml N-acetylcysteine : 200 mg/ml		3766
	Metronidazole : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Metronidazole Netilmicin sulfate		3594
	Metronidazole : 5 mg/ml Netilmicin sulfate : 1 mg/ml		958
	Metronidazole : 5 mg/ml Netilmicin sulfate : 1.4 mg/ml		1035
	Metronidazole : 5 mg/ml Oritavancin : 0.8 >> 1.2 mg/ml		3152
	Metronidazole : 5 mg/ml		3948
	Metronidazole : 5 mg/ml		4440
	Metronidazole : 5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Metronidazole : 5 mg/ml Palonosetron hydrochloride : 50 µg/ml		2228
	Metronidazole : 5 mg/ml		3967
	Metronidazole : 5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Metronidazole : 5 mg/ml Oritavancin : 2 mg/ml		3152
	Metronidazole Pantoprazole sodium		2090
	Metronidazole : 5 mg/ml	RL	4603
	Metronidazole : 5 mg/ml Paracetamol : 10 mg/ml		4742
	Metronidazole : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Metronidazole : 5 mg/ml Penicillin G potassium : 0.2 MUI/ml		631

		Metronidazole : 5 mg/ml		1415
		Metronidazole Penicillin G potassium		3594
		Metronidazole : 5 mg/ml Penicillin G potassium : 0.012 MUI/ml		1035
		Metronidazole : 5 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Metronidazole : 5 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Metronidazole : 2,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Metronidazole : 5 mg/ml Piperacillin sodium : 40 mg/ml		1692
		Metronidazole : 5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Metronidazole : 5 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Metronidazole : 5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Metronidazole : 5 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Metronidazole : 5 mg/ml Sargramostim : 10 µg/ml		335
		Metronidazole : 5 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Metronidazole : 5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Metronidazole : 5 mg/ml Tacrolimus : 1000 µg/ml		479
		Metronidazole : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Metronidazole : 5 mg/ml Teniposide : 0.1 mg/ml		905
		Metronidazole : 5 mg/ml Theophylline : 4 mg/ml		317
		Metronidazole : 5 mg/ml Thiopental sodium : 25 mg/ml		3767
		Metronidazole : 5 mg/ml Thiotepa : 1 mg/ml		249
		Metronidazole : 5 mg/ml Tobramycin sulfate : 0.8 mg/ml		1035
		Metronidazole Tobramycin sulfate		3594
		Metronidazole : 5 mg/ml Vasopressin : 0.2 UI/ml		2017
		Metronidazole : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Metronidazole : 5 mg/ml Warfarin sodium : 2 mg/ml		315



Způsoby aplikace



Odkazy

	typ	uveřejnění
3	noviny	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
11	noviny	Bailey LC, Orosz ST. Stability of ceftriaxone sodium and metronidazole hydrochloride. Am J Health-Syst Pharm 1997 ; 54: 424-427.
19	noviny	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	noviny	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	noviny	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	noviny	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	noviny	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	noviny	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	noviny	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	noviny	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
169	noviny	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	noviny	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	noviny	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

186	noviny	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	noviny	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	noviny	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	noviny	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	noviny	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
256	noviny	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
266	noviny	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
267	noviny	Nahata MC, Edmonds JJ, Morosco RS. Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25°C. Am J Health-Syst Pharm 1996 ; 53: 1046-1048.
281	noviny	Belliveau PP, Nightingale CH, Quintiliani R. Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 1561-1563.
282	noviny	Rivers TE, Webster AA. Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 2568-2570.
285	noviny	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
289	noviny	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	noviny	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	noviny	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	noviny	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	noviny	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.

316	noviny	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	noviny	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
335	noviny	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	noviny	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	noviny	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	noviny	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	noviny	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	noviny	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
434	noviny	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
479	noviny	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	noviny	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
630	noviny	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
631	noviny	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
649	noviny	Das Gupta V. Stability of ceftriaxone sodium when mixed with metronidazole injection. Int J Pharm Compound 1997 ; 1: 280-281.
671	noviny	Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture. J Parenter Sci Technol 1993 ; 47: 135-137.
905	noviny	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.

921	noviny	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	noviny	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
958	noviny	Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. Ann Pharmacotherapy 1990 ; 24: 440-442.
961	noviny	Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. J Clin Pharm Ther 1990 ; 15: 187-196.
1035	noviny	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	noviny	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1135	noviny	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1243	noviny	Rovers JP, Meneilly G, Souney PF, Rekhi GS, Drum D. The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures. Can J Hosp Pharm 1989 ; 42: 143-146.
1315	noviny	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	noviny	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	noviny	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	noviny	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1479	noviny	Digel S. Cefamandolnafat und metronidazol. Chemische stabilität in einer mischung zur intravenösen infusion. Krankenhauspharmazie 1995 ; 1: 9-12.
1490	noviny	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1605	noviny	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. Hosp Pharm 2000 ; 35: 1057-1064.
1611	noviny	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.

1625	noviny	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1692	noviny	Messerschmidt W. Pharmazeutische kompatibilität von piperacillin mit metronidazol. Krankenhauspharmazie 1998 ; 19: 226-228.
1712	noviny	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	noviny	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	noviny	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	noviny	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1802	noviny	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	noviny	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888	noviny	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	noviny	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	noviny	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	noviny	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1988	noviny	Sprandel KA, Styrszula DE, Deyo K, Sibley C, Rodvold KA. Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 88-92.
2017	noviny	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2087	noviny	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	noviny	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	noviny	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.

2228	noviny	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2233	noviny	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	noviny	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	noviny	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	noviny	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaryl with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	noviny	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	noviny	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	noviny	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	noviny	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	noviny	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3547	Laboratoř	Aztréonam (Azactam®) - Résumé des caractéristiques du produit Sanofi-Aventis France 2011
3548	Laboratoř	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3594	Laboratoř	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3728	noviny	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	noviny	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	noviny	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	plakát	Sadou Yaye H, Burtet E, Hamel C, Aljehni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014


3824	noviny	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	plakát	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakát	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3948	noviny	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	noviny	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	noviny	Staven V, Herra I, Wang S, Grönlund I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	noviny	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	noviny	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	noviny	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	noviny	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	noviny	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	noviny	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	noviny	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	noviny	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292-295.
4603	noviny	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	plakát	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021

4698	noviny	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002
4742	noviny	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	noviny	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	noviny	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	noviny	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4924	noviny	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:

Stabilis



Metronidazole



Stabilita farmaceutických přípravků

		1600 mg Metronidazole	OraPlus® >> 100 ml	25°C		90			2702
		1600 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 100 ml	25°C		90			2702
		3000 mg Metronidazole	základního sirupu >> 60 ml	23°C		93			2695
		3000 mg Metronidazole	Orablend® >> 60 ml	23°C		93			2695
		6000 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 120 ml	25°C		60			2441
		6000 mg Metronidazole	OraPlus® / OraSweet SF® (1:1) >> 120 ml	25°C		60			2441
		6000 mg Metronidazole	třešeň sirup >> 120 ml	25°C		60			2441
		3000 mg Metrogyl®	Oral Mix® >> 60 mL	25°C		90			4375
		3000 mg Metrogyl®	Oral Mix SF® >> 60 mL	25°C		90			4375
		3000 mg ® = ?	Oral Mix® >> 60 mL	25°C		90			4375
		3000 mg ® = ?	Oral Mix SF® >> 60 mL	25°C		90			4375

		2000 mg ® = ?	steviol glykosid 95% 320 mg acesulfam draslík 320 mg Omezovač hořkosti 0,32 mL banánové aroma 2,4 mL Suspendit® >>80 mL	25°C		180			4575
		4000 mg ® = ?	steviol glykosid 95% 320 mg acesulfam draslík 320 mg Omezovač hořkosti 0,32 mL banánové aroma 2,4 mL Suspendit® >>80 mL	25°C		180			4575
		3000 mg Metrogyl®	Oral Mix® >> 60 mL	4°C		90			4375
		3000 mg Metrogyl®	Oral Mix SF® >> 60 mL	4°C		90			4375
		3000 mg ® = ?	Oral Mix SF® >> 60 mL	4°C		90			4375
		3000 mg ® = ?	Oral Mix® >> 60 mL	4°C		90			4375
		6000 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 120 mL	5°C		60			2441
		6000 mg Metronidazole	OraPlus® / OraSweet SF® (1:1) >> 120 mL	5°C		60			2441
		6000 mg Metronidazole	třešeň sirup >> 120 ml	5°C		60			2441
		3000 mg Metronidazole	základního sirupu >> 60 ml	5°C		93			2695
		3000 mg Metronidazole	Orablend® >> 60 ml	5°C		93			2695
		2000 mg ® = ?	steviol glykosid 95% 320 mg acesulfam draslík 320 mg Omezovač hořkosti 0,32 mL banánové aroma 2,4 mL Suspendit® >>80 mL	5°C		180			4575
		4000 mg ® = ?	steviol glykosid 95% 320 mg acesulfam draslík 320 mg Omezovač hořkosti 0,32 mL banánové aroma 2,4 mL Suspendit® >>80 mL	5°C		180			4575
		150 mg Metrogyl®	Oral Mix® >> 3 mL	25°C		90			4375
		150 mg Metrogyl®	Oral Mix SF® >> 3 mL	25°C		90			4375
		150 mg ® = ?	Oral Mix SF® >> 3 mL	25°C		90			4375
		150 mg Metrogyl®	Oral Mix® >> 3 mL	4°C		90			4375
		150 mg ® = ?	Oral Mix SF® >> 3 mL	4°C		90			4375
		150 mg Metrogyl®	Oral Mix SF® >> 3 mL	4°C		90			4375
		30 g ®=? (Parmes pharmaceuticals)	sodíku karboxymethylcelulosy 15 g Veegum® 15 g sorbitol 70% 1200 ml Sodný sacharin 1 g methylparabenu 2 g propylparaben 400 mg Pineapple aroma destilovaná voda >> 2000 ml	25°C		90			2663



Odkazy

	typ	uveřejnění
2441	noviny	Allen LV, Jr, Erickson MA, Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2073-2078.
2663	noviny	Alexander KS, Vangala SSKS, Dollimore D. The formulation development and stability of metronidazole suspension. Int J Pharm Compound 1997 ; 1: 200-205.
2695	noviny	Donnelly Ronald F, Ying James. Stability of Metronidazole Suspensions. Int J Pharm Compound 2015 ; 19, 3: 248-251.
2702	noviny	Mathew M, Gupta VD, Bethea C. Stability of metronidazole benzoate in suspensions J Clin Pharm Ther 1994 ; 19, 1: 31-34.
4375	noviny	Jarouche M, Ibrahim M, Pearson J, Venkataya B, Low M, Rowe J. Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets. Int J Pharm Compound 2020 ;24,1:77-82
4575	noviny	Pramar Y, Mandal T, Bostanian L, Le G, Morris T, Richard A. Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt. Int J Pharm Compound 2021 ;25,2:169-175



Slovník

	Antibiotikum		Masti
	Stabilita farmaceutických přípravků		Obal
	Origine		Pomocné látky
	Teplota		Uchovávání
	Trvání stability		Biotechnologický
	konfliktní údaje		Odkazy
	Sklo		prášek
	Chráněno před světlem		Den
	Odkazy		Antiparazitikum
	injekce		Obchodní název
	Stabilita směsí		Rozpouštědlo
	Koncentrace		Sloučenina
	Glukóza 5%		Hodina
	Nespecifikováno		Žádné
	Světlo		Polyvinyl chlorid
	Chlorid sodný 0,9%		Nespecifikováno
	Faktory ovlivňující stabilitu		Glukóza 10%
	Indukuje		Rozklad
	Kompatibilita		Kompatibilní
	Okamžité srážení		Nekompatibilní
	Okamžitá zákal		Změna barvy po 4 hodinách
	Změna barvy po 12 hodinách		Nespecifikovaná nekompatibilita
	Chemická nestabilita		Ringerůs laktátový roztok
	Voda pro injekci		Parenterální výživa (binární směs)
	Zvláštní rozpouštědla		Parenterální výživa (lipidy)
	Srážení po 15 minutách		Změna barvy
	Zákal za 24 hodiny		Způsoby aplikace
	Intravenózní infúze		Perorální roztok
	plastová láhev		tablety
	stříkačka		Slovník